7-methoxy-3-(4-methoxyphenyl)-1-methyl-1H-quinolin-4-one | 327593-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-methoxy-3-(4-methoxyphenyl)-1-methyl-1H-quinolin-4-one
• 英文别名: 7-Methoxy-3-(4-methoxyphenyl)-1-methyl-1,4-dihydro-4-quinolinone；7-Methoxy-3-(4-methoxyphenyl)-1-methylquinolin-4-one
• CAS: 327593-70-4
• 化学式: C₁₈H₁₇NO₃
• 分子量: 295.338
• InChiKey: MZDPFYJMQPWMJH-UHFFFAOYSA-N

物化性质

• 沸点：
  472.7±45.0 °C(Predicted)
• 密度：
  1.194±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-methoxy-3-(4-methoxyphenyl)-1-methyl-1H-quinolin-4-one 在 吡啶 、 氢溴酸 作用下， 以58%的产率得到7-hydroxy-3-(4-hydroxyphenyl)-1-methyl-1H-quinolin-4-one
  参考文献：
  名称：

  Design and synthesis of azaisoflavone analogs as phytoestrogen mimetics

  摘要：

  A series of azaisoflavone analogs were designed and synthesized and their transactivation activities and binding affinities for ER alpha and ER beta were investigated. Among these compounds, 2b and 3a were the most potent with 6.5 and 1.1 mu M of EC50, respectively. Molecular modeling study showed putative binding modes of the compound 3a in the active site of ER alpha and ER beta, which were similar with that of genistein and provided insight of the effect of N-alkyl substitution of azaisoflavones on ER beta activity. Also, a biphasic effect of azaisoflavone analogs on MCF-7 cell growth depending on their concentrations was investigated. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.07.030
• 作为产物：
  描述：

  2’-氨基-4’-甲氧基苯乙酮 在 吡啶 、 盐酸 、 thallium(III) nitrate trihydrate 、 sodium hydride 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 22.42h， 生成 7-methoxy-3-(4-methoxyphenyl)-1-methyl-1H-quinolin-4-one
  参考文献：
  名称：

  Design and synthesis of azaisoflavone analogs as phytoestrogen mimetics

  摘要：

  A series of azaisoflavone analogs were designed and synthesized and their transactivation activities and binding affinities for ER alpha and ER beta were investigated. Among these compounds, 2b and 3a were the most potent with 6.5 and 1.1 mu M of EC50, respectively. Molecular modeling study showed putative binding modes of the compound 3a in the active site of ER alpha and ER beta, which were similar with that of genistein and provided insight of the effect of N-alkyl substitution of azaisoflavones on ER beta activity. Also, a biphasic effect of azaisoflavone analogs on MCF-7 cell growth depending on their concentrations was investigated. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.07.030

文献信息

• Pharmaceutical compositions comprising 4-quinolones for treating cancers
  申请人：Laboratoire L. Lafon

  公开号：US06645983B1

  公开（公告）日：2003-11-11

  A non-cytotoxic pharmaceutical composition acting on the proliferation of clonogenic cells in malignant tumors and including an efficient amount of a compound selected among the compounds of formula (I) and (Ia).

  一种非细胞毒性药物组合物，对恶性肿瘤中克隆细胞的增殖起作用，包括在式(I)和(Ia)的化合物中选择的有效量的化合物。
• COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES 4-QUINOLONES POUR LE TRAITEMENT DES CANCERS
  申请人：LABORATOIRE L. LAFON

  公开号：EP1202971A2

  公开（公告）日：2002-05-08
• US6645983B1
  申请人：——

  公开号：US6645983B1

  公开（公告）日：2003-11-11
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES 4-QUINOLONES
  申请人：LAFON LABOR

  公开号：WO2001012607A2

  公开（公告）日：2001-02-22

  La présente invention concerne une composition pharmaceutique non cytotoxique ayant une activité sur la prolifération de cellules clonogènes dans les tumeurs malignes et qui comprend une quantité efficace d'un composé choisi parmi les composés de formules (I) et (Ia) dans laquelle R1, R2, R3, R4, R5, R6 et R6a sont tels que définis à la revendication 1.
• [EN] USE OF 2- AND 4- QUINOLONES FOR INHIBITING INTIMAL NEO-PROLIFERATION<br/>[FR] UTILISATION DE 2- ET 4-QUINOLONES POUR INHIBER LA NEO-PROLIFERATION INTIMALE
  申请人：LAFON LABOR

  公开号：WO2002022074A2

  公开（公告）日：2002-03-21

  L'invention concerne l'utilisation de 3-aryl-2 et 4-quinolones pour la fabrication d'un médicament destiné à inhiber la néo-prolifération intimale, en particulier pour prévenir la resténose pos-angioplastie intraluminale.